Clinical TrialApr 21, 2026, 08:01 AM
Allarity's Stenoparib Shows Potential in Colorectal Cancer & Ovarian Survival
AI Summary
Allarity Therapeutics announced new data for its drug stenoparib, presented at the AACR Annual Meeting 2026. The data highlight stenoparib's potential in colorectal cancer by modulating the WNT pathway and show its proprietary Drug Response Predictor (DRP®) is associated with enhanced overall survival in ovarian cancer patients. These findings reinforce the value of DRP-based patient selection and stenoparib's unique mechanism of action, addressing significant unmet medical needs in oncology.
Key Highlights
- Stenoparib DRP® scores linked to enhanced overall survival in ovarian cancer patients.
- Stenoparib blocks WNT signaling pathway and inhibits colorectal cancer cell growth.
- Data presented at AACR Annual Meeting 2026, now available online.
- Stenoparib is a dual PARP and tankyrase inhibitor.
Price Impact
More from ALLR